S
Sverre E. Kjeldsen
Researcher at University of Oslo
Publications - 771
Citations - 95426
Sverre E. Kjeldsen is an academic researcher from University of Oslo. The author has contributed to research in topics: Blood pressure & Left ventricular hypertrophy. The author has an hindex of 94, co-authored 735 publications receiving 89059 citations. Previous affiliations of Sverre E. Kjeldsen include University of Michigan & Cornell University.
Papers
More filters
Journal Article
Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension : the LIFE study. Commentary
Ralph B. D'Agostino,Michael H. Olsen,Kristian Wachtell,Hans Ibsen,Lars H Lindholm,Björn Dahlöf,Richard B. Devereux,Sverre E. Kjeldsen,Lasse Oikarinen,Peter M. Okin +9 more
TL;DR: The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study as discussed by the authors showed that reduced albumin/creatinine ratio (UACR) and regression of left ventricular hypertrophy have been associated with lower incidence of cardiovascular events.
Journal ArticleDOI
Ambulatory Blood Pressure Monitoring (ABPM) in the VALUE Trial
Ole Lederballe Pedersen,Sverre E. Kjeldsen,G. Mancia,Asbjørn Høegholm,Jens Refsgaard,Stevo Julius +5 more
TL;DR: After one year 24-h BP was similarly reduced by the valsartan and the amlodipine based regimen, and the number of combined cardiovascular endpoints were not different in the two groups, but correlated significantly with the level of 24-H SBP and DBP.
Journal ArticleDOI
An appropriate SCORE to assess cardiovascular risk in hypertension
TL;DR: Assessment of subclinical organ damage in hypertensive patients is an attractive way to improve cardiovascular risk prediction, to individualize risk assessment and to monitor whether treatment of traditional risk factors reverses organ damage.
Journal Article
White coat hypertension and blood pressure measurement at home
TL;DR: "White-coat" hypertension, i.e. high readings in the clinic but normal readings at home, has been demonstrated in 21-58% of hypertensive subjects without end-organ injury, which should therefore be used as a supplement to monitoring by the physician.